Inmune Bio (INMB) Liabilities and Shareholders Equity (2017 - 2025)
Inmune Bio (INMB) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $32.4 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 18.23% to $32.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.2 million through Dec 2025, down 26.32% year-over-year, with the annual reading at $32.4 million for FY2025, 18.23% down from the prior year.
- Liabilities and Shareholders Equity hit $32.4 million in Q4 2025 for Inmune Bio, down from $33.4 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $107.7 million in Q3 2021 to a low of $32.4 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $63.9 million across 5 years, with a median of $61.7 million in 2021.
- Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 178.21% in 2021 and later tumbled 36.8% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $99.9 million in 2021, then fell by 18.16% to $81.8 million in 2022, then tumbled by 30.31% to $57.0 million in 2023, then plummeted by 30.59% to $39.6 million in 2024, then decreased by 18.23% to $32.4 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for INMB at $32.4 million in Q4 2025, $33.4 million in Q3 2025, and $37.7 million in Q2 2025.